Post Vaccination Adverse Events in Covid-19 Vaccine Recipients

Status Completed

Clinical Trial Summary

Covid-19 pandemic is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-Cov-2) since its outbreak 2019. Protection against Covid-19 can be achieved through global immunization. Various vaccines for SARS-Cov-2 has been registered and approved for administration in humans. It is important to understand the safety and efficacy of vaccines during robust research to develop global immunity against SARS-Cov-2. This study aimed to collect data on post vaccination adverse events in regional population of District Bahawalpur.

Clinical Trial Description

Bahawalpur District of Punjab province has population of 3.998 million and among these 2.6 million above 12 years of age are eligible for vaccination against SARS-Cov-2. 28 centers were established for vaccination within the districts at designated sites for Covid-19 vaccination. 87% targeted population has been vaccinated till 15th February 2022. Investigators designed this study to collect and evaluate data on adverse effects after vaccination of Covid-19. Investigators aimed to collect information through interviewing participants in general places of designated sites of vaccination centers established in District Bahawalpur. History will be recorded from participants and in case of adverse events detailed available history will be recorded including following adverse effects from available records on following. - Cardiovascular adverse effects - Cerebrospinal adverse events - Respiratory disturbances - Hepatobiliary disorders - Urogenital adverse effects - Musculoskeletal adverse effect - Psychological diseases - Blood biomarkers changes - Autoimmune adverse events - Allergic reactions and hypersensitivity Collected data will be summarized to get percentage of adverse effects in general population. Recorded adverse events will be assessed for their frequency in participants and association with vaccination will be assessed through employing statistical methods. Subsequent information on handling of adverse events will be recorded including - Nature of adverse event - Hospitalization and severity of adverse events - Mortality / morbidity caused by vaccination - Days of hospitalization - Changes in Blood biomarkers - Interventions adopted for adverse events - Diseased period - Covid-19 infection positivity through RT-PCR / imaging for round glass opacities / Covid-19 changes Overall efficacy and safety of vaccination will be assessed through collected data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05254977
Study type	Observational
Source	Islamia University of Bahawalpur
Contact
Status	Completed
Phase
Start date	February 26, 2022
Completion date	March 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03966391` - Effectiveness of CARD for Improving School-Based Immunizations	N/A
Completed	`NCT04530357` - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine	Phase 1/Phase 2
Terminated	`NCT03966300` - Improving the School Vaccination Experience: What CARDs Are You Going to Play?	N/A
Active, not recruiting	`NCT06286488` - Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza	Phase 4
Recruiting	`NCT05546502` - Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children	Phase 3
Active, not recruiting	`NCT05483725` - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Completed	`NCT03600428` - Safety of LAIV4 in Children With Asthma	Phase 4
Completed	`NCT03400878` - Comparing Morbidity and Mortality Effects of Two Different Strains of BCG	Phase 4
Completed	`NCT05116748` - COVID19 Vaccine in SOT Adult Recipients
Not yet recruiting	`NCT05171946` - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults	Phase 1
Recruiting	`NCT05128721` - Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)	Phase 1
Withdrawn	`NCT04894682` - Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Not yet recruiting	`NCT05387252` - Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines	N/A
Active, not recruiting	`NCT04801667` - Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients	Phase 4
Not yet recruiting	`NCT05283902` - Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
Recruiting	`NCT05095844` - National Vaccine Adverse Event Reporting Survey and Etiology
Recruiting	`NCT05315856` - Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Recruiting	`NCT05898464` - Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV	Phase 4
Recruiting	`NCT05212792` - Genomics and COVID-19 Vaccine Adverse Events
Recruiting	`NCT05258708` - COVID-19 Vaccine Reactogenicity and Immunogenicity